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Pong-Term Safety of Intravascular
ltrasound in Nontransplant,
onintervened, Atherosclerotic Coronary Arteries
ntoine Guédès, MD, Pierre-Frédéric Keller, MD, Philippe L. L’Allier, MD, Jacques Lespérance, MD,
ean Grégoire, MD, Jean-Claude Tardif, MD
ontreal, Quebec, Canada
OBJECTIVES The goal of this study was to demonstrate that intravascular ultrasound (IVUS) examination
of native coronary arteries does not result in an acceleration of the atherosclerotic process.
BACKGROUND Intravascular ultrasound is increasingly used to assess the effects of pharmacologic agents on
atherosclerosis.
METHODS Intravascular ultrasound examinations of one coronary artery and coronary angiography were
performed in 525 patients at baseline. Patients then underwent a follow-up angiogram 18 to
24 months later. All end points were evaluated in IVUS-related and non-IVUS arteries using
quantitative coronary analysis. The study end points were the coronary change score
(per-patient mean of minimum lumen diameter changes for all lesions measured), occurrence
of new coronary lesions, and progression of preexistent lesions at follow-up. Acute
angiographic and clinical complications were also analyzed.
RESULTS Coronary change score was 0.06  0.23 mm and 0.05  0.21 mm for IVUS-related and
non-IVUS arteries, respectively (p  0.35). The increase in percent diameter stenosis from
baseline to follow-up was 0.8  6.7% and 1.2  7.0% in the IVUS-related and non-IVUS
arteries (p  0.29). New lesions occurred in 3.6% and 3.9% of IVUS-related and non-IVUS
arteries, respectively (p  0.84). When all coronary lesions were considered, the incidence of
lesion progression was not significantly different between IVUS-related (11.6%) and
non-IVUS (9.8%) arteries. Coronary spasm occurred in 1.9% of IVUS procedures, and there
was one case of acute occlusion with no long-term sequelae.
CONCLUSIONS Intravascular ultrasound does not significantly accelerate atherosclerosis in native coronary
arteries and can be used safely to assess progression/regression in clinical trials. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.063Cardiol 2005;45:559–64) © 2005 by the American College of Cardiology Foundation
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ctherosclerosis imaging has taken on increasing importance
n the understanding of the natural history of coronary
rtery disease and the processes leading to luminal narrow-
ng, as well as the assessment of therapy efficacy (1).
ntravascular ultrasound (IVUS) is an imaging method that
ses miniaturized ultrasound transducers at the tip of
atheters to provide cross-sectional images of both the
oronary arterial lumen and wall with excellent resolution.
he precise assessment of both plaque burden and vascular
emodeling has resulted in the increasing use of IVUS as the
rimary efficacy assessment measure of several antiathero-
clerotic approaches in randomized clinical trials (2–5).
dvantages of IVUS include its ability to reveal antiathero-
clerotic effects within a relatively short period of time and
ith a reasonable sample size, in contrast to trials assessing
linical events; IVUS can also help to determine dose-
esponse relationships in the development of novel pharma-
ologic agents (5).
Because of these advantages of IVUS, it is imperative to
emonstrate the safety of this catheter-based imaging mo-
ality, especially when used strictly for research purposes in
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004, accepted October 26, 2004.ative coronary arteries. Although the short-term safety of
VUS has been shown in large multicenter registries (6,7),
he data on long-term safety after coronary imaging are
uch more limited. Indeed, while three studies have re-
orted follow-up after initial IVUS examination of trans-
lant coronary arteries (8–10), there are presently no pub-
ished data on long-term safety in nontransplant, native
therosclerotic coronary arteries that have never been
reated by percutaneous coronary intervention (PCI). In
ddition, there is a concern that catheter-induced endothe-
ial damage may lead to an acceleration of the atheroscle-
otic process in instrumented vessels (11). Therefore, we
ssessed in this study the long-term safety of IVUS up to
wo years after the initial examination of atherosclerotic
ative coronary arteries.
ETHODS
atient population. The study population consisted of 525
atients of the Avasimibe and Progression of coronary
esions assessed by intravascular UltraSound (A-PLUS)
rial from 25 centers in Canada, the U.S., Europe, Australia,
nd South Africa (3). Patients needed to have suspected or
roven coronary artery disease and be scheduled for clini-
ally indicated coronary angiography. All patients under-
ent a baseline coronary angiogram and IVUS after giving
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as done after 18 to 24 months of follow-up.
The target coronary artery for IVUS needed to have a
0% to 50% diameter stenosis in a vessel2.5 mm by visual
ngiographic assessment to facilitate the IVUS examination.
he target coronary artery also had to be free of filling
efects suggestive of thrombus and should not have been
nfluenced by prior or present therapeutic PCI. Patients
ndergoing PCI of a nontarget artery at the time of
creening catheterization could be included.
VUS procedure. Intravascular ultrasound studies were
erformed using 3.2-F or 2.9-F 30-MHz IVUS catheters
Boston Scientific, Natick, Massachusetts). Intracoronary
itroglycerin (150 g) was administered before the IVUS
xamination. The IVUS catheter was advanced distally, at
east 40 mm beyond the coronary artery ostium, to a
ecognizable landmark (arterial branch). The guiding cath-
ter was disengaged before imaging to allow visualization of
he aorto-ostial junction. The transducer was then pulled
ack automatically at a speed of 0.5 mm/s up to the guiding
atheter, with the use of a validated motorized device. A
etailed running audio commentary was recorded during
he pullback. A second pullback was then performed in the
ame coronary artery using the same guidelines to ensure
igh-quality imaging (12). To ensure each center was
nitially capable of proper collection of IVUS data, the core
aboratory reviewed two test-run examinations before ap-
roving the clinical site.
ngiographic procedure. Attention was paid to have
dentical conditions during both angiographic examinations
t baseline and follow-up (catheters, contrast media, pro-
ections, recordings). In particular, intracoronary nitroglyc-
rin (150 g) was administered into each coronary artery
efore angiographic injection. The segments of interest
ere visualized in multiple transverse and sagittal views to
learly separate stenoses from branches, minimize foreshort-
ning, and obtain views as perpendicular as possible to the
ong-axis of the segments to be analyzed. All patients had
ntracoronary contrast injections after the IVUS examina-
ion was performed to allow detection of coronary spasm,
hrombus, dissection, or any other angiographically visible
cute complication.
uantitative coronary analysis (QCA) of angiograms. All
oronary angiograms were analyzed at our QCA core
aboratory by means of the Clinical Measurements Solu-
ions system (QCA-CMS, Version 5.1; MEDIS Imaging
ystems, Leiden, the Netherlands) (13). The automatic
Abbreviations and Acronyms
IVUS  intravascular ultrasound
MLD  minimum lumen diameter
PCI  percutaneous coronary intervention
QCA  quantitative coronary analysisdge detection program determines the vessel contours by cssessing brightness along scanlines perpendicular to the
essel center (14). To provide absolute numbers for vessel
izes, a calibration factor expressed in mm/pixel is deter-
ined by applying the edge-detection procedure for parallel
oundaries on a non-tapering section (of known size) of the
ontrast-filled catheter. The computer automatically calcu-
ates the minimum lumen diameter (MLD), reference
iameter, percentage diameter stenosis, and stenosis length.
The QCA was performed by technicians supervised by an
xperienced physician (14–16) in matched projections from
he baseline and follow-up coronary angiograms. For each
esion in the study end point segments, an end-diastolic
rame from both angiograms (baseline and follow-up) was
elected with identical angulation that best showed the
tenosis at its most severe degree with minimal foreshort-
ning and branch overlap. The study end point segments
ncluded all those of a diameter 2.0 mm with stenosis
20% at baseline and those with new lesions at follow-up.
ll coronary arteries intervened with PCI were excluded
rom the analysis (from the aorto-ostial junction to the
istal segment, and its branches).
Among study end point segments, IVUS-related (instru-
ented) and non-IVUS (non-instrumented, control) arter-
es were identified. All coronary segments from the aorto-
stial junction to the distal segment reached by the tip of the
VUS guidewire were considered as IVUS-related seg-
ents. The non-IVUS (control) segments were defined as
ll coronary artery segments without any instrumentation
or IVUS or past or present PCI. The number of coronary
egments measured by QCA in the IVUS-related (instru-
ented) and non-IVUS (control) coronary arteries was
ependent on the criteria described above.
omparison between IVUS-related and control coronary
rteries from baseline to follow-up coronary angiography
sing QCA. The coronary change score was defined as the
er-patient mean of the MLD changes of all coronary
egments analyzed by QCA between baseline and follow-up
16). A change in MLD0.4 mm represents approximately
wice the SD of repeat measurements of lesions filmed at
ne- to six-month intervals in previous studies (14,15) and
as, therefore, taken to represent a true change, either
rogression or regression. A new coronary lesion was
efined as a stenosis that was not apparent on the first
ngiogram or was 20% in diameter stenosis but that
arrowed by0.4 mm in MLD at the follow-up angiogram
n QCA. Lesion progression was considered present when
t least one lesion at baseline (20%) showed a worsening
f MLD 0.4 mm at the follow-up angiogram. For each
atient, these end points were evaluated in the IVUS-
elated segments and the non-IVUS (control) coronary
rtery segments.
cute angiographic and clinical complications. All IVUS
xaminations performed at baseline were analyzed for acute
linical complications. A total of 475 IVUS examinations
ere suitable for the analysis of acute angiographic compli-ations. For the remaining 50 patients, there was no
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February 15, 2005:559–64 Long-Term Safety of IVUS in Coronary Arteriesdequate angiographic recording to assess the presence or
bsence of spasm or other complications after IVUS instru-
entation. Such patients were excluded from the statistical
nalysis of acute angiographic complications, although they
ere all reported as normal by the operators who performed
he coronary angiograms. Acute angiographic complications
ere considered along the entire IVUS-related artery from
he aortocoronary ostial junction to the tip of the guidewire.
etailed clinical manifestation of any angiographic compli-
ation was reported for each patient.
tatistical analysis. Continuous data are presented as
ean  SD. For each patient, the study end points were
valuated in the IVUS-related coronary segments and the
on-IVUS (control) coronary segments. Comparisons be-
ween IVUS-related arteries and control arteries were done
sing a repeated measures analysis of variance for coronary
hange score, lesion length and reference diameter at
aseline, and using McNemar tests for new coronary lesions
nd progression of coronary lesions. Paired t tests were used
or baseline lesion length and baseline reference diameter for
he patients with both IVUS-related arteries and non-IVUS
rteries (n  387). All analyses were done with SAS
version 8.2, SAS Institute, Cary, North Carolina). A value
f p  0.05 was considered significant.
able 1. Characteristics of the Patients at Baseline (n  525)
en (%) 425 (81%)
ge (yrs, mean  SD) 58  10
moking (%) 95 (18%)
ypertension (%) 289 (55%)
iabetes (%) 89 (17%)
tatin therapy (%) 462 (88%)
Atorvastatin 252 (48%)
Simvastatin 142 (27%)
Pravastatin 68 (13%)
lasma lipids, mean (SE)
Total cholesterol (mg/dl) 165 (2)
LDL cholesterol (mg/dl) 92 (1.6)
HDL cholesterol (mg/dl) 44 (0.8)
Triglycerides (mg/dl) 149 (5.8)
DL  high-density lipoprotein; LDL  low-density lipoprotein.
Table 3. Quantitative Coronary Analysis of An
IVUS-Rela
(n  499
Minimum lumen diameter (mm)
Baseline 2.26
Follow-up 2.20
Coronary change score (mm) 0.06
Percent diameter stenosis (%)
Baseline 30.1
Follow-up 30.8
Change 0.8
Lesion length (mm)
Baseline 10.5
Follow-up 10.3
Reference diameter (mm)
Baseline 3.22
Follow-up 3.17IVUS  intravascular ultrasound.ESULTS
atients’ characteristics at baseline are summarized in Table 1.
he mean age of the patients was 58 years, and 55% of them
ad hypertension. The vast majority (88%) of patients were
reated with statins: 48% of patients were treated with
torvastatin, 27% with simvastatin, and 13% with pravasta-
in. Mean low-density lipoprotein cholesterol was 92 mg/dl
2.42 mmol/l), and mean high-density lipoprotein choles-
erol was 44 mg/dl (1.20 mmol/l). Mean plaque volume on
VUS was 199  71 mm3 (Table 2). Mean duration of
ollow-up was 19 months. Quantitative coronary analysis
esults at baseline and follow-up are summarized in Table 3.
oronary change score. The coronary change score, de-
ned as the per-patient mean of MLD changes for all
esions measured, was available in 499 patients for IVUS-
elated (instrumented) arteries and in 400 patients for
on-IVUS (non-instrumented, control) arteries. The lipid
rofiles were similar in both groups of patients (Table 4).
he distribution of coronary arteries was as follows: left
nterior descending, circumflex, and right coronary arteries
epresented 35%, 23%, and 42%, respectively, of IVUS-
elated arteries and 28%, 41%, and 31%, respectively, of
on-IVUS arteries. There were 1,068 lesions studied in
VUS-related arteries and 1,024 lesions in non-IVUS arter-
es. The coronary change score was 0.06  0.23 mm for
he IVUS-related arteries and 0.05  0.21 mm for the
on-IVUS coronary arteries (p 0.35) (Fig. 1). Among the
87 patients in whom both IVUS-related and non-IVUS
rteries were assessed, the coronary change score was 0.05
0.21 mm and 0.04  0.21 mm for IVUS-related
able 2. Intravascular Ultrasound Results at Baseline
laque volume (mm3) 199  71
otal vessel volume (mm3) 438  127
umen volume (mm3) 239  83
ercent atheroma volume (%) 45  9
argest plaque area (mm2) 4.5  2.0
ata are presented as mean  SD.
rams
rteries
ents)
Non-IVUS Arteries
(n  400 Patients) p Value
8 1.90  0.50 0.001
1 1.85  0.50
3 0.05  0.21 0.35
32.8  9.6 0.001
34.0  10.6
1.2  7.0 0.29
9.0  3.8 0.001
9.0  3.8
7 2.82  0.54 0.001
6 2.79  0.55giog
ted A
Pati
 0.4
 0.5
 0.2
 6.8
 9.0
 6.7
 5.0
 5.1
 0.5
 0.5
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Table 5).
ew coronary lesions. New coronary lesions were present
n 18 of 499 (3.6%) of patients for IVUS-related arteries and
n 17 of 400 (4.3%) of patients for non–IVUS-related
rteries. Among the 387 patients in whom both IVUS-
elated and non-IVUS arteries were assessed, new coronary
esions were present in 14 of 387 (3.6%) and 15 of 387
3.9%) of patients for IVUS-related and non-IVUS (con-
rol) arteries, respectively (p 0.84) (Fig. 1). Among the 14
atients with new coronary lesions in IVUS-related arteries
t follow-up, 2 of 14 (14%) also had new coronary lesions in
on-IVUS coronary arteries and 12 of 14 (86%) had not.
mong the 373 patients without new lesions in IVUS-
elated coronary arteries at follow-up, 13 of 373 (3%) had
ew lesions in non-IVUS coronary arteries and 360 of 373
97%) had not.
rogression of coronary lesions. Lesion progression oc-
urred in 58 of 499 (11.6%) patients for IVUS-related
rteries and in 39 of 400 (9.8%) patients for non-IVUS
control) arteries. To assess statistical significance of these
ates, patients with both evaluable IVUS-related arteries
nd evaluable non-IVUS coronary arteries were taken (n 
87). Lesion progression was present in 45 of 387 (11.6%)
f patients in IVUS-related coronary arteries and in 36 of
87 (9.3%) of patients in non-IVUS coronary arteries (p 
.27) (Fig. 1). Among the 45 patients with lesion progres-
ion in IVUS-related coronary arteries at follow-up, 7 of 45
16%) also had lesion progression in non-IVUS coronary
rteries and 38 of 45 (84%) had not. Among the 342
igure 1. Bar graphs for the coronary change score (left panel) and for the
ategorical end points (right panel) for all lesions in the intravascular
ltrasound (IVUS)-related (instrumented) and non-IVUS (control) coro-
ary arteries. *To assess statistical significance for the rates of categorical
nd points, patients with both evaluable IVUS-related coronary arteries
nd evaluable non-IVUS arteries were taken and McNemar tests were done
Table 4. Plasma Lipids
IVUS-Related Arteri
(n  499 Patients)
Total cholesterol 165  26
LDL cholesterol 91  20
HDL cholesterol 44  11
Triglycerides 149  73
Data are presented as mg/dl, mean  SD.
HDL  high-density lipoprotein; IVUS  intravascularc
see text). Solid bars  IVUS-related arteries (instrumented); ruled bars
non-IVUS arteries (control).atients without progression of coronary lesions in IVUS-
elated arteries at follow-up, 29 of 342 (8%) had lesion
rogression in non-IVUS coronary arteries and 313 of 342
92%) had not.
cute angiographic complications and clinical events. The
ost frequent side effect was coronary spasm, which oc-
urred in nine procedures out of a total of 475 IVUS
xaminations for an incidence of 1.9%. Coronary spasm was
elieved in all cases by the intracoronary injection of
itroglycerin.
Only one major complication occurred during these
VUS examinations performed at baseline, which was an
cclusion at the site of a preexisting 50% diameter stenosis
f the second left posterolateral coronary artery. This was
uccessfully treated by balloon angioplasty, and the artery
as angiographically normal at 24-month follow-up. There
ere no episodes of guidewire entrapment, embolism,
hrombus, unstable angina, myocardial infarction, or death
elated to the IVUS examinations.
ISCUSSION
his is the first clinical study that demonstrates that IVUS
xamination of native atherosclerotic coronary arteries does
ot accelerate disease progression evaluated after up to 24
onths of follow-up. The coronary change score as well as
he incidence of new coronary lesions and disease progres-
ion were similar in IVUS-related and non-IVUS coronary
rteries. Intravascular ultrasound is increasingly used as the
rimary efficacy assessment measure of several antiathero-
clerotic approaches in randomized clinical trials (2–5). The
recise evaluation of plaque burden and vascular remodeling
ith IVUS indeed makes it an excellent imaging modality
or clinical trials of atherosclerosis progression/regression
1). It is, however, extremely important to demonstrate the
afety of this invasive diagnostic procedure, especially when
erformed for research purposes. Although its short-term
afety has been well demonstrated (6,7), the data on the
ong-term safety of IVUS was much more limited.
isease progression in coronary arteries. The one-year
afety of IVUS imaging has been assessed by serial QCA of
ngiograms in three studies involving only cardiac trans-
lant recipients (8–10). The first two studies were small and
nvolved 38 and 86 heart transplant patients and did not
how any significant difference between instrumented and
on-instrumented vessels in terms of percentage or absolute
Non-IVUS Arteries
(n  400 Patients) p Value
165  25 0.85
91  20 0.85
44  10 0.85
149  72 0.82
und; LDL  low-density lipoprotein.eshange in angiographic lumen diameter one year after the
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February 15, 2005:559–64 Long-Term Safety of IVUS in Coronary Arteriesnitial IVUS examination (8,9). Ramasubbu et al. (10)
ompared vessel diameter, frequency, and severity of coro-
ary stenosis between instrumented and non-instrumented
oronary arteries in 226 heart transplant recipients one to
wo years after IVUS examination. In that study, a compar-
son with 130 control coronary arteries allowed the demon-
tration of the absence of disease acceleration in the 548
VUS-related vessels in these transplant patients, but QCA
easurements of matched angiograms were actually per-
ormed in only 31 patients (10).
Although these data in heart transplant recipients were
eassuring, transplant arteriopathy is, in part, an immune-
ediated disease that is not identical to atherosclerosis (17).
n addition, stenosis at the time of IVUS examination was
ess severe in these cardiac transplant patients than in our
tudy of native coronary arteries. To our knowledge, our
tudy is the first one to evaluate prospectively the effect of
VUS examination on disease progression in nontransplant,
onintervened, atherosclerotic native coronary arteries.
cute angiographic complication and clinical events.
he most frequently encountered complication in previous
eports was coronary spasm, which occurred in approxi-
ately 2% to 3% of patients during interventional and
iagnostic IVUS procedures and usually responded rapidly
o administration of intracoronary nitroglycerin (1,6,7).
ajor and acute procedural complications potentially asso-
iated with IVUS imaging were rare and occurred during
nterventional cases (6). In one large multicenter registry
nvolving more than 2,200 patients assessing its short-term
afety, there was no occurrence of myocardial infarction
ssociated with IVUS imaging performed for diagnostic
ndications (6). In our study, the incidence of coronary
pasm was 1.9%, and there was one case of acute occlusion
equiring balloon angioplasty that did not result in myocar-
ial infarction or long-term sequelae.
tudy limitations. Quantitative coronary analysis has lim-
tations when used for the assessment of atherosclerosis
Table 5. Quantitative Coronary Analysis in th
Non-IVUS Arteries
IVUS-Rela
(n  387
Minimum lumen diameter (mm)
Baseline 2.25
Follow-up 2.20
Coronary change score 0.05
Percent diameter stenosis (%)
Baseline 30.3
Follow-up 30.9
Change 0.7
Lesion length (mm)
Baseline 10.6
Follow-up 10.4
Reference diameter (mm)
Baseline 3.23
Follow-up 3.18
IVUS  intravascular ultrasound.rogression, the most important one being its inability to cllow direct visualization of the coronary arterial wall; QCA
evertheless remains the best imaging method currently
vailable to evaluate the long-term safety of IVUS. How-
ver, atherosclerotic changes that would not result in lumi-
al changes could not be analyzed. Because there was 80%
ower to detect a difference of 0.04 mm in coronary change
core, minimal changes in lumen dimensions might not
ave been detected. The long-term follow-up without
ignificant deleterious angiographic effects clearly supports
he safety of IVUS imaging. The safety of the procedure as
emonstrated in this study may be dependent on the
haracteristics of the patients. Performing IVUS examina-
ion on severely stenotic and calcified coronary arteries in
atients with comorbidities may not necessarily be as safe.
he IVUS arteries were indeed larger at baseline than
on-IVUS arteries in our study.
onclusions. This study has shown that diagnostic IVUS
maging does not significantly accelerate atherosclerosis in
ative human coronary arteries and can be used safely to
ssess disease progression/regression in clinical trials.
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Patients With Both IVUS-Related and
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ents)
Non-IVUS Arteries
(n  387 Patients) p Value
6 1.90  0.50 0.001
9 1.85  0.50
1 0.04  0.21 0.50
33.0  9.6 0.001
34.0  10.2
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9.0  3.8
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